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FIGURE 1 Intracardiac Echocardiographic Images of Intracardiac Device Lead and Tricuspid Regurgitant Severity
With Different Etiologies
Intracardiac echocardiographic imaging with the transducer placed in the right atrium in 3 patients. The ﬁrst patient had severe left ventricular
(LV) dysfunction (left ventricular ejection fraction [LVEF] ¼ 20%), normal right ventricular (RV) size, and pulmonary artery systolic pressure
(PASP) estimated at 55 mm Hg, an implantable cardioverter deﬁbrillator (ICD) lead (arrow) placed at the RV anterolateral wall with
impingement of the posterior leaﬂet (A), and moderately eccentric tricuspid regurgitation (TR) with color Doppler imaging (CDI) (B). The
second patient had moderate LV dysfunction (LVEF ¼ 35%); enlarged RV and tricuspid annulus; PASP of 51 mm Hg; an ICD lead (rightward
arrows) placed at the RV apex; multiple small thrombi (leftward arrow) attached at the lead (C); and severely centralized TR with CDI, which
shows that the lead (arrows) is slightly impinging the posterior leaﬂet (D). The third patient had arrhythmogenic RV cardiomyopathy, enlarged
RV and tricuspid annulus, PASP of 33 mm Hg, LVEF ¼ 30%, a centralized location of ICD lead (arrows) placed at the RV apex (E), and
moderately to severely centralized TR with CDI (F). Ao ¼ aortic root; RA ¼ right atrium; RVOT ¼ RV outﬂow tract; tv ¼ tricuspid valve.
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284–7.REPLY: Tricuspid Regurgitation Severity
Associated With Positioning of RV
Lead or Other Etiology Assessed
by Intracardiac EchocardiographyWewould like to thank Dr. Ren and colleagues for their
interest and feedback and appreciate the opportunity
to reply. Themain limitation of our study (1) is that it is
retrospective; therefore, assumptions of cause and
effect regarding tricuspid regurgitation (TR) are
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1287impossible to make. As a “proof of concept,” we used
transthoracic echocardiography to evaluate the fea-
sibility of visualizing tricuspid valve leaﬂetmotion and
device location in 3 dimensions (3D) as well as the de-
gree of TR. In our single-center study, 3D evaluation of
lead location was feasible in 90% of studies and an
association did exist between lead position and degree
of TR (1).
As opposed to mitral regurgitation, TR lacks stan-
dardized recommendations for severity and data
for etiology (2). For TR severity assessment, a
comprehensive “semiquantitative” approach is re-
commended due to the lack of standardized
reference values (2). Three-dimensional effective
regurgitant oriﬁce area and regurgitant fraction may
provide more precise volumes; however, they are
more difﬁcult to reliably obtain and lack reference
values.
Tricuspid valve regurgitation, regardless of the
etiology, is associated with high morbidity and mor-
tality. In a study by Nath et al. (3), the investigators
showed that signiﬁcant TR was associated with
worse outcomes. In their study (n ¼ 5,223), the
severity of TR correlated with worse outcomes,
independent of right ventricular size, left ventri-
cular function, or pulmonary artery systolic pressures
(3). Furthermore, Lin et al. (4) described device-
associated TR requiring cardiac surgery as well as
several mechanisms leading to valve malfunction,
including adherence, impingement, perforation, or
entanglement (4).
Ren et al. have experience with intracardiac echo-
cardiography and should be applauded for their
efforts using this imaging modality in clinical prac-
tice. This imaging modality may be useful to guide
lead placement in the future; however, routine
intracardiac echocardiography to guide device place-
ment is not the standard of care and should be
considered investigational.
We proposed 3D echocardiographic guidance as a
possible way to limit device lead-associated TR;
however, several questions need to be answered
prior to considering a prospective clinical trial to
investigate this issue:
1. Do device leads remain in the same location after
insertion?
2. Is guidance of lead location possible? If so, what
imaging modality would best guide lead place-
ment (3D transthoracic echocardiography, 2D/3D
transesophageal echocardiography, or intracardiac
echocardiography)?
Once these questions are answered with ran-
domized, prospective studies, the clinical utility oflead placement under imaging guidance could be
determined.Anuj Mediratta, MD
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45:1672–5.Imaging Findings in
Aortic Intramural HematomaI greatly enjoyed reading the comprehensive iReviews
article from Baliga et al. (1). The authors have pro-
vided a detailed summary of the topic with com-
pelling illustrations and multidetector computed
tomography images. However, I feel it is necessary
to point out an error in the description of Figure 8
that could be misleading to readers. The images in
question are described as depicting an intramural
hematoma; however, it is rather showing an example
of an aortic mural thrombus. Intramural hematoma
can be recognized by its location within the
aortic media, deep to the intima, well-illustrated by
Figure 2 (1) of the review. As noted in the text,
hematoma can be localized to this area by iden-
tiﬁcation intimal calciﬁcations that are displaced by
the thickened wall. In the provided Figure 8 (1),
there is no displaced intimal calciﬁcation, but
rather, the area labeled as hematoma is located within
the vessel calciﬁcations, clearly depicted on the
noncontrast image. This conﬁrms the diagnosis of
mural thrombus rather than intramural hematoma.
Furthermore, acute intramural hematoma will be
highly attenuated on noncontrast computed tomog-
raphy (2), which is not the case in Figure 8 (1) of
